Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
Roger J Lewis, Jason T Connor, John R Teerlink, James R Murphy, Leslie T Cooper, William R Hiatt, Eric P Brass, Roger J Lewis, Jason T Connor, John R Teerlink, James R Murphy, Leslie T Cooper, William R Hiatt, Eric P Brass
Abstract
Background: Claudication secondary to peripheral artery disease (PAD) is associated with substantial functional impairment. Phosphodiesterase (PDE) inhibitors have been shown to increase walking performance in these patients. K-134 is a selective PDE 3 inhibitor being developed as a potential treatment for claudication. The use of K-134, as with other PDE 3 inhibitors, in patients with PAD raises important safety and tolerability concerns, including the induction of cardiac ischemia, tachycardia, and hypotension. We describe the design, oversight, and implementation of an adaptive, phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication.
Methods: The study design was a double-blind, multi-dose (25 mg, 50 mg, and 100 mg of K-134), randomized trial with both placebo and active comparator arms conducted in the United States and Russia. The primary objective of the study was to compare the highest tolerable dose of K-134 versus placebo using peak walking time after 26 weeks of therapy as the primary outcome. Study visits with intensive safety assessments were included early in the study period to provide data for adaptive decision making. The trial used an adaptive, dose-finding strategy to efficiently identify the highest dose(s) most likely to be safe and well tolerated, based on the side effect profiles observed within the trial, so that less promising doses could be abandoned. Protocol specified criteria for safety and tolerability endpoints were used and modeled prior to the adaptive decision making. The maximum target sample size was 85 subjects in each of the retained treatment arms.
Results: When 199 subjects had been randomized and 28-day data were available from 143, the Data Monitoring Committee (DMC) recommended termination of the lowest dose (25 mg) treatment arm. Safety evaluations performed during 14- and 28-day visits which included in-clinic dosing and assessments at peak drug concentrations provided core data for the DMC review. At the time of review, no subject in any of the five treatment arms (placebo, three K-134-containing arms, and cilostazol) had met pre-specified definitions for resting tachycardia or ischemic changes on exercise ECG. If, instead of dropping the 25-mg K-134 treatment arm, all arms had been continued to full enrollment, then approximately 43 additional research subjects would have been required to complete the trial.
Conclusions: In this phase II, dose-finding trial of K-134 in the treatment of stable intermittent claudication, no concerning safety signals were seen at interim analysis, allowing the discontinuation of the lowest-dose-containing arm and the retention of the two highest-dose-containing arms. The adaptive design facilitated safe and efficient evaluation of K-134 in this high-risk cardiovascular population.
Trial registration: ClinicalTrials.gov: NCT00783081.
Figures
References
- Welten GM, Schouten O, Hoeks SE. et al.Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51:1588–96. doi: 10.1016/j.jacc.2007.11.077.
- Steg PG, Bhatt DL, Wilson PW. et al.One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–206. doi: 10.1001/jama.297.11.1197.
- Hirsch AT, Criqui MH, Treat-Jacobson D. et al.Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24. doi: 10.1001/jama.286.11.1317.
- Hirsch AT, Haskal ZJ, Hertzer NR. et al.ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47:1239–312. doi: 10.1016/j.jacc.2005.10.009.
- Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA, McDermott M. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010;15:181–8. doi: 10.1177/1358863X10361545.
- Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;48:2539–45. doi: 10.1016/j.jacc.2006.07.064.
- Packer M, Carver JR, Rodeheffer RJ. et al.Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468–75. doi: 10.1056/NEJM199111213252103.
- Gaydos B, Anderson KM, Berry D. et al.Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development. Drug Information Journal. 2009;43:539–56.
- Antonijevic Z, Pinheiro J, Fardipour P, Lewis RJ. Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III. Statistics in Biopharmaceutical Research. in press .
Source: PubMed